Prognosis and therapy of secondary myelodysplastic syndromes

Haematologica

Volumn 83, Issue 6, 1998, Pages 543-549

  Estey, Elihu H ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Allogeneic transplant; AML type chemotherapy; Erythropoietin; G CSF; International Prognostic Scoring system; Topotecan

Indexed keywords

AMIFOSTINE; ANTINEOPLASTIC AGENT; AZACITIDINE; BUSULFAN; CHELATING AGENT; CYCLOPHOSPHAMIDE; CYTARABINE; DEFEROXAMINE; ERYTHROPOIETIN; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IDARUBICIN; RETINOIC ACID; TOPOTECAN;

ACUTE GRANULOCYTIC LEUKEMIA; BLOOD TRANSFUSION; BONE MARROW TRANSPLANTATION; CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHROMOSOME ABERRATION; CLINICAL TRIAL; CONTROLLED STUDY; DRUG INDUCED DISEASE; HUMAN; IRON CHELATION; IRON OVERLOAD; MAJOR CLINICAL STUDY; META ANALYSIS; MYELODYSPLASTIC SYNDROME; RANDOMIZED CONTROLLED TRIAL; REVIEW; SECOND CANCER; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTE TRANSFUSION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; RADIOTHERAPY;

EID: 0031876366     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. Vallespi T, Torrabadela M, Julia A, et al. Myelodysplastic syndromes: a study of 101 cases according to the FAB classification. Br J Haematol 61:83-92, 1985.
2. Kerkhofs H, Hermans, J, Haak HL, et al. Utility of the FAB classification for myelodysplastic syndromes: investigation of prognostic factors in 237 cases. Br J Haematol 1987; 65:73-81.
3. Mufti GJ, Stevens JR, Oscier DG, et al. Myelodysplastic syndromes: a scoring system with prognostic significance. Br J Haematol 1985; 59:425-33.
4. Sanz GH, Sanz MA, Vallespi T, et al. Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients. Blood 1989; 74:395-408.
5. Aul C, Gattermann N, Heyll A, et al. Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system. Leukemia 1992; 6:52-59.
6. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89:2079-88.
7. Kantarjian H, Keating M, Walters R, et al. Therapy-related leukemia and myelodysplastic syndrome: clinical cytogenetic, and prognostic features. J Clin Oncol 1986; 4:1738.
8. Cohen A, Martin M, Schwartz E. Depletion of excessive liver iron stores with desferrioxamine. Br J Haematol 1984; 58:369.
9. Wolfe L, Oliveri W, Sallan D, et al. Prevention of cardiac disease by subcutaneous desferrioxamine in patients with thalassemia major. N Engl J Med 1985; 312:1600.
10. Hoffbrand AV, Gorman A, Laulicht M, et al. Improvement in iron status and liver function in patients with transfusional iron overload with long-term subcutaneous desferrioxamine. Lancet 1979; i:947.
11. Brittenham GM. Iron-chelating agents. Curr Ther Hematol Oncol 1987; 3:149.
12. 9/L platelets [abstract]. Blood 1996; 88(suppl 1):443a.
13. Wandt H, Frank M, Schneider C, Ehninger G, Link H. The 10000/μL trigger compared to 20,000/μL for prophylactic platelet transfusion in AML: a prospective comparative multicenter study [abstract]. Blood 1996; 88(suppl 1):443a.
14. Lindberg-Hellström E. Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies. Br J Haematol 1995; 89:67-71.
15. Rose EH, Abels RI, Nelson RA, et al. The use of r-HuEpo in the treatment of anemia related to myelodysplasia (MDS). Br J Haematol 1995; 89:831-7.
16. Negrin RS, Stein R, Doherty K, et al. Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: evidence for in vivo synergy. Blood 1996; 87:4076-81.
17. Thompson J, Gilliland, Prchal J, et al. The use of GM-CSF ± r-HuEPO for the treatment of cytopenias associated with myelodysplastic syndromes (MDS) [abstract]. Blood 1996; 88(suppl 1):337a.
18. Cheson BD, Arbuck SG, Phillips PH, NCI. Clinical trials (referral resource). Oncology: September 1995.
19. List AF, Heaton R, Glinsmann-Gibson B, et al. Amifostine promotes multilineage hematopoiesis in patients with myelodysplastic syndrome (MDS): results of a phase I/II clinical trial [abstract]. Blood 1996; 88(suppl 1):453a.
20. Rosenfeld SJ, Kimball J, Vining D, Young NS. Intensive immunosuppression with antithymocyte globulin and cyclosporine as treatment for severe acquired aplastic anemia. Blood 1995; 85:3058-5.
21. Molldrem J, Stetler-Stevenson M, Mavroudis D, Young NS, Barrett AJ. Antithymocyte globulin (ATG) abrogates cytopenias in patients with myelodysplastic syndromes [abstract]. Blood 1996; 88(suppl 1):454a.
22. Greenberg P, Taylor K, Larson R et al. Phase III randomized multicenter trial of G-CSF vs observation for myelodysplastic syndromes (MDS) [abstract]. Blood 1993; 82(suppl 1):196a.
23. Cheson BD, Jasperse DM, Simon R, et al. A critical appraisal of low-dose cytosine arabinoside in patients with acute non-lymphocytic leukemia and myelodysplastic syndromes. J Clin Oncol 1986; 4:1857-64.
24. Miller KB, Kim K, Morrison FS, et al. Evaluation of low dose ara-C versus supportive care in the treatment of myelodysplastic syndromes: an intergroup study by the Eastern Cooperative Oncology Group and the Southwest Oncology Group [abstract]. Blood 1988; 72(suppl 1):215a.
25. Bolwell BJ, Cassileth PA, Gale RP. Low dose cytosine arabinoside in myelodysplasia and acute myelogenous leukemia: a review. Leukemia 1987; i:575-9.
26. Estey E, Thall P, Beran M, Kantarjian H, Pierce S, Keating M. Effect of diagnosis (RAEB, RAEB-t, or AML) on outcome of AML-type chemotherapy. Blood 1997; 90:2969-77.
27. Anderlini P, Pierce S, Kantarjian H, et al. AML-type chemotherapy for myelodysplasia [letter]. J Clin Oncol 1996; 14:1404-5.
28. Fenaux P, Morel P, Rose C, et al. Prognostic factors in adult de novo myelodysplastic syndromes treated by intensive chemotherapy. Br J Haematol 1991; 77:497-501.
29. Wijermans PW, Krulder JWM, Huijgens PC, Neve P. Continuous infusion of low-dose 5-aza-2′-deoxycytidine in elderly patients with high-risk myelodysplastic syndrome. Leukemia 1997; 11:1-5.
30. Beran M, Kantarjian H, O'Brien S.Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 1996; 88:2473-9.
31. Beran M, Kantarjian H, Keating M et al. Topotecan + ara-C in newly-diagnosed MDS [abstract]. Blood 1997; 90(suppl 1); in press.
32. Fenaux P, Chastang C, Chomienne C, et al. Treatment of newly diagnosed acute promyelocytic leukemia (APL) by all trans retinoic acid (ATRA) combined with chemotherapy: the European experience. Leuk Lymphoma 1995; 16:4311-7.
33. Estey E, Beran M, Pierce S, Kantarjian H, Keating M. ATRA may improve results of chemotherapy in poor prognosis non-APL AML and MDS: a randomized study [abstract]. Blood 1997; 90(suppl 1); in press.
34. Anderson JE, Appelbaum FR, Schoch G, et al. Allogeneic marrow transplantation for myelodysplastic syndrome with advanced disease morphology: a phase II study of busulfan, cyclophosphamide, and total-body irradiation and analysis of prognostic factors. J Clin Oncol 1996; 14:220-6.
35. O'Donnell MR, Long GD, Parker PM, et al. Busulfan/cyclophosphamide as conditioning regimen for allogeneic bone marrow transplantation for myelodysplasia. J Clin Oncol 1995; 13:2973-79.
36. Anderson JE, Appelbaum FR, Storb R. An update on allogeneic marrow transplantation for myelodysplastic syndrome. Leuk Lymphoma 1995; 17:95-9.
37. Sutton L, Chastang C, Ribaud P, et al. Factors influencing outcome in de novo myelodysplastic syndromes treated by allogeneic bone marrow transplantation: a long-term study of 71 patients. Blood 1996; 88:358-65.
38. Anderson JE, Appelbaum FR, Schoch G, et al. Allogeneic marrow transplantation for refractory anemia: a comparison of two preparative regimens and analysis of prognostic factors. Blood 1996; 87:51-8.
39. Ferrant A, Labopin M, Frassoni F, et al. Karyotype in acute myeloblastic leukemia: prognostic significance for bone marrow transplantation in first remission: a European Group for blood and marrow transplantation study. Blood 1997; 90:2931-8.
40. Szydlo R, Goldman JM, Klein JP, et al. Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings. J Clin Oncol 1997; 15:1767.
41. Giralt S, Estey E, Albitar M, et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997; 89:4531-6.